Tags : ReveraGen

Top 20

Top 20 Biopharma Deal Terminations of 2020 Based on Total

The biopharma industry saw numerous deal terminations in 2020. Clinical and regulatory results, change in control limitations, and strategic reprioritizations were among the most common reasons for deal termination. Sanofi and Hanmi’s agreement in 2015 ranked first under which Hanmi regained WW rights to its protein/peptide discovery technology, lapscovery. The second position goes to the […]Read More

Pharma

Idorsia Transfers its Agreement with ReveraGen to Santhera for Vamorolone

Shots: Idorsia transfers its development & commercialization agreement with ReveraGen to Santhera, whereby Santhera shall replace Idorsia as a party to the agreement.  Santhera to get an exclusive license, including sublicensing rights, for vamorolone in all indications globally, including Japan and South Korea and a share in expected PR voucher In exchange for the revised […]Read More